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Cyclosporine A enhances platelet aggregation. In view of the reported
increase in thromboembolic episodes following cyclosporine A (CyA)
therapy, the effect of this drug on platelet aggregation and thromboxane
A2 release was investigated. The addition of CyA, at therapeutic
concentrations to platelet rich plasma from normal subjects in vitro was
found to increase aggregation in response to adrenaline, collagen and
ADP. Ingestion of CyA by healthy volunteers was also associated with
enhanced platelet aggregation. The CyA-mediated enhancement of
aggregation was further enhanced by the addition in vitro of therapeutic
concentrations of heparin. Platelets from renal allograft recipients
treated with CyA also showed hyperaggregability and increased throm-
boxane A2 release, which were most marked at "peak" plasma CyA
concentration and less so at "trough" concentrations. Platelet hyperag-
gregability in renal allograft patients on long—term CyA therapy tended
to revert towards normal following the replacement of CyA with
azathioprine. Hypertensive patients with renal allografts on nifedipine
therapy had normal platelet function and thromboxane release in spite
of CyA therapy. These observations suggest that CyA-mediated platelet
activation may contribute to the pathogenesis of the thromboembolic
phenomena associated with the use of this drug. The increased release
of thromboxane A2 (a vasoconstrictor) may also play a role in mediating
CyA-related nephrotoxicity.
Cyclosporine A (CyA) has an important role in the prevention
of rejection in renal transplant recipients [1, 2]. Recently,
however, it has been suggested that CyA treatment in this
patient group is associated with an increased incidence of throm-
boembolic complications [3, 4]. Glomerular capillary thrombi
have been reported to occur with increased frequency in renal
allograft recipients with CyA nephrotoxicity when compared
with those who have acute allograft rejection [5, 6].
A recent study from Vanrenterghem et al [3] showed that
CyA-treated patients had a number of hemostatic changes
which favor thrombosis, and which may therefore account for
the observed high incidence of thromboembolic events in these
patients. This study, however, left some questions unanswered.
For example, although there was a suggestion that CyA levels
correlated with ADP-induced platelet aggregation, this was not
quantified. Furthermore, despite platelet hyperaggregability no
associated change in thromboxane A2 (TXA2) was demon-
strated.
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The present study attempts to clarify some of these unre-
solved issues. Thus we have addressed the problem of CyA
levels and measured platelet TXA2 release in response to
several agonists in renal transplant recipients. We have also
assessed the effect of CyA on platelets under strictly controlled
conditions, in vitro and after ingestion by healthy volunteers.
Methods
Study 1: Platelet aggregation following the in vitro addition
of CyA to platelets obtained from healthy volunteers
Blood was collected (from an antecubital vein) with minimum
stasis from seven healthy volunteers. The blood was anticoag-
ulated with trisodium citrate (9 parts blood: 1 part citrate) as
previously described [7:1. All the volunteers denied taking any
drugs for at least two weeks prior to sampling. Platelet rich
plasma (PRP) and platelet poor plasma (PPP) were prepared by
centrifugation at room temperature [7]. The maximum delay
between sampling and starting centrifugation was 10 minutes.
Following centrilugation, PRP was kept at 37°C for all subse-
quent experiments as cooling is known to alter platelet function
[81. Aggregation was expressed as the percentage fall in optical
density three minutes after adding the aggregating agent [7].
The difference in optical density between PRP and PPP was
defined as 100%. Aggregations were carried out in Chronolog dual
channel aggregometers (Coulter Electronics, Luton, Bedsford,
UK) [7].
For each subject, experiments were run in pairs; one ag-
gregometer channel contained PRP with the appropriate volume
of saline only (control) and the other channel a solution of CyA
(test). CyA was dissolved in a minimum amount of absolute
ethanol and then diluted in physiological saline. Appropriate
volumes of absolute ethanol were added to the saline control.
The final concentration of absolute ethanol in the cuvette was
160 mg/liter. The concentrations of CyA used were selected to
reflect the plasma levels in renal transplant patients treated with
this drug [9]. The concentrations of the agonists (Table 1) were
submaximal (producing 0 to 50% aggregation in the saline
controls: ADP, 1 to 2 psnol/liter; adrenaline, 1 to 3 mol/liter;
collagen, 0.15 to 0.50 mg/liter) so as to highlight enhancement
[10]. The PRP was first incubated with CyA or saline for two
minutes, and aggregation was then induced with the appropriate
agonist. In other experiments, CyA (125 to 500 ng/ml) was
added to PRP and the baseline tracing followed for up to 15
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Table 1. Median (range) percentage platelet aggregation following the
in vitro addition of CyA to PRP prepared from healthy controls(N = 7)
fi
concentration
ng/ml
Adrenaline-induced
aggregation
Control CyA
Collagen-induced
aggregation
Control CyA
ADP-induced
aggregation
Control CyA
125 334—P < O.05-+57
(25—44) (36—69)
04—NS—#36
(0—50) (19—68)
184—NS—44
(11—46) (18—56)
250
500
234—P < O,Ol--*63
(10—SO) (40—81)
26+-P < O.0l—*61
(15—SO) (25—85)
04—P < 0.Ol—+47
(0—47) (22—73)
04—P < O.01—*59
(0—49) (28—71)
l3P < OM1—U40
(9—47) (26—66)
22+-P < O.Ol—+53
(12—49) (30—72)
P values obtained by comparing control aggregation with aggregation
in the presence of CyA (Wilcoxon test)
minutes to establish whether CyA alone could induce aggrega-
tion (more than 20% fall in optical density).
Additive-free CyA was from Sandoz Ltd. (Basle, Switzer-
land).
Study 2: Platelet function following the ingestion of CyA by
healthy volunteers
Ten fasting healthy volunteers (7 males; 3 females), median
age 28 years (range: 24 to 37 years), from whom informed
consent had been obtained, were included in the study. No
other drugs had been taken for at least two weeks before the
study. CyA (Sandimmun; Sandoz) was administered in a dose
of 15 mg per kg body weight. CyA was dissolved in 50 ml of
chocolate milk (Unigate Dairies).
Blood was collected and PRP and PPP was prepared as
described in Study 1.
Submaximal agonist doses were used and percentage aggre-
gation was calculated three minutes after adding the agonist, as
described in Study 1, except that saline or CyA in solution were
not added in vitro. Platelet counts in PRP were monitored using
a Coulter ZM counter (Coulter).
Plasma CyA concentrations were estimated by an HPLC
method as previously described [9, 11].
Four control subjects were sampled after taking the same
amount of chocolate milk without CyA.
Study 3: Effect of normal plasma ionic calcium
concentrations and therapeutic levels of heparin on
CyA -mediated enhancement of platelet aggregation, in vitro
In the experiments described in Studies 1 and 2, blood was
collected in citrate. This anticoagulant functions by calcium
chelation; ionic calcium levels are therefore very low. It was
thus necessary to establish whether CyA-mediated enhance-
ment of platelet aggregation could be observed at normal plasma
ionic calcium concentrations. This objective was achieved by
preparing PRP using heparin (Thromboliquine, Organon By,
Oss, Holland) as anticoagulant. The procedures and number of
control subjects was as described in Study 1, except that the
anticoagulant volume was only 4 jd of heparin dissolved in
physiological saline to achieve a final concentration of 2 U/mI of
blood. Baseline aggregation tracings were found to be unstable
and a considerable drift was often noted, even in the absence of
aggregating agents. Aggregation patterns were not consistent
Table 2. Median and (range percentage platelet aggregation in
heparinized and citrated PRP (N = number of subjects evaluated)
Heparin
Aggregating
Agent Saline
0.5—1.0
U/mi
CyA
(500 ng/mt) CyA + heparin
Heparinized PRP
ADP (N 7) 34 50*(0.5 to 1.0 (13—50) (19—75)
mol/liter)
Adrenaline 24 45(N = 3)
(0.5 to 1.0 (16—36) (38—52)
jmol/1iter)
Citrated PRP
ADP (N 7) 9 368 l8a
(1.0 to 1.5 (2—20) (28—60) (8—33) (32—75)
mol/liter)
Adrenaline 5 44* 19 71b
(N= 3)
(0.5 to 1.0 (2—15) (18—67) (6—48) (40—83)
mo1Iliter)
Statistical analysis (Wilcoxon test):
saline vs. CyA or heparin alone: 8 P < 0.01
CyA + heparin vs. CyA or heparin alone: bP < 0.01
except with ADP as the aggregating agent; therefore the seven
samples were tested only with this agonist. Three of these
samples (those with the most stable baseline tracings) were also
evaluated with adrenaline as the aggregating agent. The con-
centrations of ADP, adrenaline and CyA used are shown in
Table 2. The concentrations of aggregating agents (ADP, adren-
aline) were set at lower levels than in Study 1 to allow
enhancement with CyA and heparin alone and a further en-
hancement of aggregation when both these drugs are added to
PRP.
Blood was also collected in citrate (Study 1) from the same
subjects and on the same occasion as the heparinized samples.
PRP from these citrated samples was prepared simultaneously
with that of the heparinized samples in the same centrifuge.
Aggregations were then carried out: heparinized samples first
and citrated samples second on one occasion and the sequence
reversed on the next occasion. Platelet counts were measured
as described in Study 2. The count in the citrated samples was
corrected for dilution so that it could be compared with counts
in heparinized PRP.
The purpose of simultaneously collecting citrated and hepa-
rinized samples was: (a) to establish whether heparin caused a
significant fall in platelet count, as has been previously sug-
gested [reviewed in 121; (b) to compare aggregation responses in
citrated and heparinized PRP; (c) to establish whether the
enhancing effect of CyA was "additive" to the enhancement
which is already known to occur with heparin [10, 12, 13]. This
was achieved by adding heparin (final concentration: 0.5 to 1.0
pJml, that is, therapeutic concentrations [10]) to citrated PRP;
and (d) to compare ionic calcium concentrations in citrated and
heparinized PRP. This was achieved using a Radiometer ICA 1
ionic calcium analyzer (Copenhagen, Denmark). Appropriate
control and calibration samples (supplied by the manufacturers)
were used before and after each measurement.
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Study 4: Platelet function in renal allograft recipients taking
CyA
Renal allograft recipients (8 males; 11 females), median age
27 years (range: 19 to 46 years) with stable, functioning grafts
(median plasma creatinine 168 tmolIliter; range: 81 to 300
mo1/liter) were studied. Median time since transplantation was
eight months (range: 2 to 20 months). All patients were taking
CyA orally, median dose 175 mg b.d. (range 100 to 350 mg b.d.)
and prednisolone (CP Pharmaceuticals, Wrexham, UK), me-
dian dose 12.5 mg o.d. (range 8.5 to 20 mg o.d.). Eight patients
were also taking nifedipine SR (Adalat Retard, Bayer UK Ltd.),
median dose 30 mg b.d. (range 20 to 40 mg b.d.). Other drugs
taken were ranitidine (11 patients) metoprolol (7), furosemide
(5), spironolactone (4), bumetanide (3), warfarin (2), and cimet-
idine (1).
Patients were sampled fasting in the morning 12 hours fol-
lowing their previous CyA dose (the "trough" sample) and then
two hours following CyA ingestion (the "peak" sample). Blood
was collected, prepared and aggregation studies conducted as
described in Study 2.
Eleven patients not taking nifedipine had platelet thrombox-
ane A2 (TXA2) release assessed as previously described [7].
Briefly, platelet aggregation was induced as described in Study
2 by agonist concentrations (ADP 10 /Lmollliter; collagen 1
mg/liter; adrenaline S molJliter), which produce maximal ag-
gregation and therefore measurable quantities of thromboxane
B2 (TXB2; the stable, spontaneous breakdown product of
TXA2). Three minutes after adding the agonists, the PRP was
collected and added to absolute ethanol to stop the reaction.
This sample was then stored at —40°C until measurement of
TXB2, in a single batch, using a specific radioimmunoassay [7].
For comparison, eight healthy subjects (Same age and sex
distribution as in Study 2) were also sampled.
Study 5: Platelet function in renal allograft recipients
converted from CyA to azathioprine
Renal allograft recipients (3 males, 4 females), median age 38
years (range 21 to 47 years) with stable, functioning grafts
(median creatinine 133 molIliter; range 115 to 186 mol/1iter)
were studied. Median time since transplantation was 15 months
(range 12 to 17 months). Prior to changeover, all patients were
taking CyA (median dose 150 mg b.d.; range 135 to 200 mg b.d.)
and prednisolone (median dose 10 mg o.d.; range: 8.5 to 11 mg
o.d.). Three patients were taking ranitidine and three were
taking metoprolol. CyA was withdrawn over a three week
period following a standard protocol. Azathioprine was intro-
duced and the dose of prednisolone was increased temporarily
during the period of conversion. Renal allograft function im-
proved following conversion (median creatinine 106 prnol/liter;
range 88 to 159 mol/liter).
Patients were sampled while taking CyA and four to eight
weeks after having ceased taking the drug, when the dose of
prednisolone was again the same as pre-changeover. 'Trough'
samples defined in Study 4 were collected during CyA therapy,
and patients were sampled at approximately the same time in
the morning when they were no longer taking this drug.
Aggregation studies and platelet counts were carried out as
described in Study 2.
Table 3. Median (range) percentage platelet aggregation and platelet
count in PRP in samples obtained 0, 2, and 4 hours following
ingestion of CyA, (15 mg/kg body weight), by normal volunteers(N = 10)
Platelet aggregation PRP platelet
count medianCollagen
Sampling 0.5 mgI Adrenaline I ADP 2 (range) X
time liter /.Lmol l tunol l' 109/liter
0 33 28 35 410
(pre-CyA) (0—80) (7—78) (5—87) (310—480)
2 hours 46
(0—92)
52b
(20—83)
63
(15—9 1)
350
(260—450)
4 hours 12
(0—74)
7
(0—29)
49
(0—90)
400
(490—570)
Median and (range) plasma CyA levels were 546(212—1232) at 2 hand
560 (292—1136) ng/ml at 4 hours.
a P< 0.05comparing pre-CyA % aggregation with % aggregation at 2
hours
b P < 0.01 comparing % aggregation at 2 hours with % aggregation at
0 and 4 hours
Other values not significant. P values were calculated using the
Wilcoxon test
Whole blood platelet counts (Coulter Counter S plus) before,
and six weeks after, conversion were also analyzed retrospec-
tively in these seven patients and in an additional four patients
converted from CyA. Median number of counts sampled per
patient pre-conversation were 21 (range 8 to 28) and post-
conversion were 9 (range 6 to 22).
Presentation of results and statistical analysis
Results are presented as median and range. In Study 1, the
results in the presence of CyA were compared with those with
vehicle only present, using a paired Wilcoxon rank sum test. In
Study 2, the values in the baseline sample were compared with
those two and four hours after the ingestion of CyA, using the
same test as in Study 1. In Study 3, results were compared using
a paired Wilcoxon test, since all samples were obtained, pre-
pared and treated simultaneously. In Study 4, "peak" and
"trough" samples were compared using a paired Wilcoxon test.
Patient values were compared with controls using an unpaired
Mann-Whitney test. In Study 5, values during CyA treatment
and those after cessation of therapy were compared using a
paired Wilcoxon rank sum test. All the tests used were two-
tailed.
Results
Study 1: Platelet aggregation following the in vitro addition
of CyA to platelets obtained from healthy volunteers
There was a significant enhancement of platelet aggregation
following the addition of CyA, in vitro (Table 1). This effect was
observed with all three aggregating agents, ADP, adrenaline
and collagen. The enhancement was best observed at final
concentrations of CyA of 250 and 500 ng/ml of PRP. CyA
concentrations below 125 nglml did not achieve any consistent
enhancement of aggregation. CyA alone did not induce any
aggregation in PRP.
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Table 4. Median (range) percentage aggregation (in PRP) in samples obtained at "Peak" and "Trough" CyA levels from renal allograft
recipients on and off nifedipine
.
Aggregating
agent
Patients taking CyA (N = II)
Patients t
and nif
(N
aking CyA
edipine
8) Controls
N = 8Trough PeakTrough Peak
Adrenaline (prnol/ liter)
0.2 45
(0—64)
64b
(0—77)
6
(0—47)
9
(0—60)
6
(0—21)
0.5 48
(5—87)
7l
(0—95)
44
(23—84)
56
(13—86)
20
(0—33)
5.0 65
(13—93)
—P < 0.05—* 78
(14—99)
78
(44—88)
73
(52—84)
66
(54—85)
Collagen (mg/liter)
0.5 68
(0—91)
73
(15—93)
47
(14—80)
42
(0—77)
42
(12—60)
1.0 66
(49—97)
—P<0.05—* 80
(54—95)
75
(33—93)
76
(45—86)
70
(62—84)
ADP (mol/liter)
1 24
(0—89)
35
(0—89)
6
(0—50)
30
(0—77)
10
(0—50)
2 61
(0—99)
74b
(2—100)
59
(14—90)
69
(12—80)
52
(7—63)
10 64
(44—90)
4—P < 0.0l— 83
(60—100)
69
(53—95)
68
(60—100)
75
(63—89)
PRP platelet counts 260 280 330 290 360
median (range) x 109/liter (150—660) (230—650) (190—420) (180—460) (280—430)
Median (range) plasma 92 386 74 270
CyA concn. (nglml) (64—114) (282—714) (54—130) (142—652)
P values peak vs. trough concentrations as shown in table (Wilcoxon test)
CyA treated vs. control: P < 0.05 level (Mann-Whitney test)b CyA treated vs. control: P < 0.02 level (Mann-Whitney test)
Study 2: Platelet function following the ingestion of CyA by
healthy volunteers
There was significant enhancement of platelet aggregation
following the ingestion of CyA. This enhancement was no
longer present 4 h after the ingestion of CyA. (Table 3)
The PRP platelet count fell at two hours and then tended to
return to baseline values (Table 3). These changes, however,
were not statistically significant.
The ingestion of chocolate milk drink had no effect on platelet
aggregation.
Study 3: Effect of normal plastna ionic calcium
concentrations and therapeutic levels of heparin on
CyA -mediated enhancement of platelet aggregation, in vitro
CyA significantly enhanced platelet aggregation in heparin-
ized PRP despite the unstable baseline tracings (Methods).
Aggregation was considerably more enhanced in heparinized
PRP when compared with citrated PRP. Thus for ADP-induced
aggregation, in saline and CyA containing PRP, the percentage
aggregation was significantly greater (P < 0.01; Wilcoxon test)
in heparinized PRP. In citrated PRP, both CyA and heparin
significantly enhanced platelet aggregation. However, aggrega-
tion in PRP containing both CyA and heparin was always
greater than that in PRP containing the same amount of only
one of these drugs. Therefore, the enhancing effects of CyA and
heparin were somewhat 'additive'. PRP platelet counts were
significantly lower (P < 0.01; Wilcoxon test) in heparinized PRP
(352; 288 to 508) when compared with corresponding values in
citrated PRP (462; 336 to 576). The ionic calcium concentrations
were: 1.12 to 1.21 mmollliter in heparinized PRP and 0.09 to
0.11 mmollliter in citrated PRP.
Study 4: Platelet function in renal allograft recipients taking
CyA
There was significant enhancement of platelet aggregation in
the "peak" samples when compared with the "trough" sam-
ples in the patients not taking nifedipine but not in those taking
this drug (Table 4).
When compared with healthy control subjects, aggregation
was significantly enhanced in the patients not taking nifedipine;
this enhancement was not statistically significant in the patients
taking nifedipine.
PRP platelet counts were not significantly different when
"trough" and "peak" counts were compared in the patient
groups (Table 4). The median PRP platelet counts in the patient
groups were lower than those in the healthy controls, but this
did not achieve statistical significance.
When compared with control samples, platelet TXB2 release
was significantly enhanced in platelets of patients (N = 11)
taking CyA only, but there was no significant difference when
"peak" and "trough" samples were compared (Table 5).
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Patients
Control 3 12.5 17
Subjects (<1—5.5) (3—24) (10—27)
Study 5: Platelet function in renal allograft recipients
converted from CyA to azathioprine
There was a general trend for platelet aggregation to decrease
following cessation of CyA therapy (Table 6). This only achieved
statistical significance (P < 0.05) with aggregation induced by
0.5 jsmollliter adrenaline.
The PRP platelet count increased significantly (P < 0.01)
after cessation of CyA therapy (Table 6).
Whole blood platelet counts also increased significantly (P <
0.01) from median 205 x l09/liter (range 130 to 320) before
conversion to median 245 x 109/liter (range 170 to 380) follow-
ing conversion.
Discussion
This study shows conclusively that CyA enhances platelet
aggregation (and TXA2 release) in all test systems evaluated.
This supports an earlier report [31 of enhanced ADP-induced
platelet aggregation in CyA-treated renal allograft recipients.
These findings may have clinical implications not only with
regard to the reported increased incidence of large vessel
thrombosis in CyA-treated allograft recipients [3], but also in
contributing to the nephrotoxic effects of the drug by promoting
local vasoconstriction and glomerular arteriolar thrombosis [5,
14—17].
Platelets from healthy volunteers displayed increased activa-
tion in vitro at final concentrations of added CyA which
reflected the levels achieved in clinical practice (100 to 200
ng/ml) [9]. The demonstration of CyA-mediated enhancement
of aggregation in heparinized PRP shows that this phenomenon
occurs at normal ionic calcium concentrations. Furthermore,
the citrated-heparinized PRP experiments show that heparin-
and CyA-mediated enhancement of aggregation are 'additive'.
This latter observation may be of relevance since heparin alone
activates platelets in patients undergoing dialysis [13]. The
ingestion of a single dose of CyA in normal volunteers caused
increased platelet activation, maximal at two hours but revert-
ing to normal at four hours. This occurred in the face of a
further increase in CyA concentration at four hours, and may
therefore indicate that prolonged exposure to CyA is required
to activate platelets consistently.
This reversal of hyperaggregability was not observed in
patients taking CyA, since there was significant platelet activa-
tion at "trough" levels with an additional significant increase in
aggregation at "peak" concentrations. Platelet TXA2 release
Aggregating agent Pre-conversion Post-conversion Controls
Adrenaline pmol/liter
0.2 13 0
(0—47) (0—73)
6
(0—2 1)
0.5 52 —P < 0.05—* 19
(30—76) (0—63)
19
(0—38)
5.0 76 71
(35—78) (56—100)
66
(54—85)
Collagen mg/liter
0.5 53 16
(0—62) (12—85)
42
(12—60)
1.0 69 68
(49—85) (40-79)
70
(62—84)
ADP nol/liter
1 35 16
(0—74) (0—6 1)
10
(0—50)
2 64 54
(28—90) (28—82)
52
(7—63)
10 75 71
(60—83) (61—97)
75
(63—89)
PRP platelet counts 200 4—P < 0.Ol—* 290
Median (range)x l0/ (180—260) (270—500)
liter
Median trough pre-conversion plasma CyA was 109 (86—123) ng/ml. P
values obtained by comparing percentage aggregation and PRP counts
pre- and post-conversion (Wilcoxon test) are shown between arrows in
the table. P values comparing controls with preconversion samples
(Mann-Whitney Test) were a P < 0.002. There were no significant
differences between control and post-conversion samples
was significantly enhanced in the CyA-treated group; however,
no "peak-trough" difference was observed, probably because
we used agonists that induced maximal aggregation in order to
achieve measurable levels of TXB2. Nifedipine, used for the
control of hypertension, prevented platelet activation at "trough"
levels and blunted the "peak-trough" difference in aggregation.
This effect may relate to the known inhibitory action of this
drug on platelet aggregation and TXA2 release [reviewed in 18].
Conversion of patients from CyA to azathioprine resulted in
a trend towards normal platelet activity. This was accompanied
by a significant rise in platelet counts, thus suggesting that CyA
enhances platelet consumption.
There are many similarities between our findings and those of
the Leuven group [31. For example, they suggested a relation
between CyA levels and enhanced aggregation in their patients.
We showed that "peak" aggregation was greater than "trough"
aggregation. They [3] did not show enhanced platelet TXA2
release, despite reporting hyperaggregability. We also could not
demonstrate enhanced TXA2 release using collagen (the only
agonist used by the Leuven group [3]), but the release of this
prostanoid was markedly increased in response to ADP or
adrenaline. Unimpressive enhancement of collagen-induced
platelet aggregation in ex-vivo studies was a feature shared by
both studies. The reason for this is not clear.
Following the initial observation [3] of an increased incidence
of thrombotic episodes in the large vessels of renal allograft
recipients receiving CyA, attempts to define the true incidence
of this complication have been contradictory [4, 19, 20]. A
number of variables identified in our study may have contnb-
uted to the inconsistency of the previous results and should
Table 5. Platelet TXB2 release in patients (N = 11) taking CyA only
and in healthy control subjects (N = 8)
ADP 10 mol/ Adrenaline 5 prnol/ Collagen 1 mg/
liter liter liter
Trough Peak Trough Peak Trough Peak
13b 12b 18 18.sa 11 12.5
(1.5—23) (1—22) (1.5—32.5) (3—41) (3.5—27) (3—31)
Table 6. Median (range) percentage platelet aggregation (in PRP) in
patients (N = 7) converted from CyA to azathiopnne and controls(N=8)
TXB2 release is expressed as median and (range) ng TXB2 per l0
platelets
a Control vs. CyA: P = 0.05, Mann-Whitney test' Control vs. CyA: P < 0.002, Mann-Whitney test
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therefore be considered in future studies. For example, "peak"
levels may relate to the initiation of thrombosis, and therefore
the mode and frequency of administration of CyA (such as,
oral, bolus i.v., and i.v. infusion) may be important in this
context. Concurrent therapy with nifedipine or heparin may
also modify the incidence of thrombotic complications.
The histopathology of CyA nephrotoxicity is non-specific,
and debate surrounds its differentiation from allograft rejection
[21, 22]. Glomerular capillary thrombosis may be a feature of
rejection, but has been observed more commonly in association
with CyA nephrotoxicity [5]. The mechanism of this phenom-
enon is not clear, but increased platelet activation, associated
TXA2-driven vasoconstriction [14] and the reduction of vascu-
lar PGI2 (a vasodilator) and PGE2 production reported [23—25]
with CyA may play a role. In this context it is of relevance that
CyA enhances TXA2 synthesis by the kidney [26]. It is also of
interest that increased urinary TXB2 excretion has been asso-
ciated with renal allograft rejection [27]. The functional impor-
tance of glomerular thrombosis in patients receiving CyA is not
established, but it probably contributes to renal impairment by
reducing renal blood flow producing glomerular and tubular
ischemia [14, 27, 28]. The inhibition of platelet aggregation may
therefore be of clinical benefit by mitigating nephrotoxicity.
The coagulation system is also altered in CyA-treated pa-
tients, and some of these changes would favor thrombosis [3].
For example, elevated plasma fibrinogen concentrations [3]
increase plasma viscosity, adversely influence coagulation and
enhance platelet aggregation [29].
In addition to these observations, CyA has been associated
with the occurrence of a hemolytic uremic syndrome (HUS) [5,
6, 16, 17, 30, 31]. The pathogenesis of this complication is not
clear but the deficiency of a prostacyclin-stimulating factor has
been suggested [23, 31]. Previous observations in thrombotic
thrombocytopenic purpura (TTP), a variant of HUS, have
included increased platelet activation [32]. Our findings in
CyA-treated patients would be consistent with a mechanism
involving increased platelet activation as a contributory factor
in producing this syndrome in transplant recipients.
In conclusion, CyA causes platelet activation, demonstrated
in vitro, in normal volunteers and in renal allograft recipients.
The effect appears to be concentration-dependent and is atten-
uated by concurrent nifedipine administration. This platelet
activation may contribute to the nephrotoxicity of CyA treat-
ment and to the reports of an increased incidence of thrombo-
embolic phenomena associated with the use of this drug.
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